Faithward Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Faithward Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-28,414	Closed	-$1.76M	–	275
2022 Q3	$1.76M	Buy	28,414 +3,839	+16%	+$268K	0.42%	53
2022 Q2	$1.96M	Buy	24,575 +192	+0.8%	+$18.2K	0.44%	50
2022 Q1	$2.56M	Buy	24,383 +1,243	+5%	+$121K	0.5%	47
2021 Q4	$2.49M	Sell	23,140 -8,682	-27%	-$947K	0.47%	48
2021 Q3	$3.49M	Buy	31,822 +57	+0.2%	+$5.92K	0.68%	39
2021 Q2	$2.97M	Buy	31,765 +1,236	+4%	+$114K	0.59%	44
2021 Q1	$2.81M	Sell	30,529 -123	-0.4%	-$10.4K	0.63%	43
2020 Q4	$2.24M	Sell	30,652 -1,163	-4%	-$86.4K	0.98%	24
2020 Q3	$2.47M	Buy	+31,815	New	+$2.19M	0.6%	47

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Faithward Advisors's HZNP Position: Q4 2022 in Review

Faithward Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022, closing a stake of 28,414 shares — an estimated $1.76M sold.

Faithward Advisors first reported a position in HZNP in Q3 2020 and held it in 9 quarters. The position peaked at $3.49M in Q3 2021. 615 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

Faithward Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Faithward Advisors sold 28,414 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $1.76M.
Faithward Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2020 and held it in 9 quarters.
Faithward Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $3.49M in Q3 2021.
615 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on Faithward Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.